

Predictors of chronic liver disease in individuals with human immunodeficiency virus infection

Nila Rafiq,* Maria Stepanova,** Brian Lam,* Fatema Nader,*,** Manirath Srishord,*,** Zobair M. Younossi*,**

* Center for Liver Diseases and Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA.

** Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA.

ABSTRACT

Introduction. Chronic liver disease (CLD) is becoming a major cause of mortality in patients who are positive with human immunodeficiency virus (HIV). Our aim was to assess the prevalence of CLD in HIV+ individuals. **Material and methods.** We utilized the National Health and Nutrition Examination Survey (1999-2008) to assess the association of CLD with HIV infection. In eligible participants (18-49 years), HIV infection was defined as positive anti-HIV by enzyme immunoassay further confirmed by Western blot. The diagnosis of CLD included chronic hepatitis C (CH-C), alcohol-related liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD). Clinic-demographic and laboratory parameters were used to assess differences between those with and without HIV infection. **Results.** 14,685 adults were included. Of those, 0.43 ± 0.08% were HIV-positive and 13.8% had evidence of CLD, including 26.3% in HIV-positive individuals and 13.7% in HIV-negative controls ($p = 0.0341$). In the U.S. population, independent predictors of CLD included HIV positivity [OR = 1.96 (1.02-3.77), $p = 0.04$], older age [OR = 1.03 (1.02-1.03), $p < 0.0001$], male gender [OR = 2.15 (1.89-2.44), $p < 0.0001$] and obesity [OR = 2.10 (1.82-2.43), $p < 0.0001$], while African American race/ethnicity was associated with lower risk for CLD [OR = 0.68 (0.58-0.80), $p < 0.0001$]. **Conclusions.** CLD is common in HIV positive individuals. With successful long term treatment of HIV, management of CLD will continue to remain very important in these patients.

Key words. HIV. CLD. HCV. NAFLD. ALD.

INTRODUCTION

According to the World Health Organization (WHO), as of 2011, 34 million people are infected with human immunodeficiency virus (HIV).¹ From the time when the combination antiretroviral therapy (cART) was developed, there has been a significant decrease in deaths related to acquired immunodeficiency syndrome (AIDS).² Although AIDS was the 8th cause of mortality prior to 1996, in 2012, it is no longer in the top 10 causes of death.³ In fact, recent studies have shown that HIV-positive individuals on cART have greater than 50% chance of dying for reasons not related to AIDS.^{4,5}

The most common non-AIDS related cause of death is liver disease which accounts for approximately 14-18% of deaths.⁶ One study to provide evidence to support this shift in the cause of death collected data related to adverse events of Anti-HIV Drugs (D.A.D study). This study followed 23,441 HIV individuals over 5 years during which 1,235 deaths were registered.⁴ Although in the HIV+ cohort, AIDS remained the leading cause of death at 31.1%, liver disease was the second leading cause of death at 14.5%. Of the liver-related causes of death, 66% were due to hepatitis C (HCV), 16.9% were due to hepatitis B (HBV), and 7.1% were due to co-infection to both HCV and HBV. In addition to establishing liver disease as the second most common cause of death, this study also established a strong association between liver related deaths and the extent of advanced immunodeficiency.⁴

This and other studies continue to provide strong evidence that CLD is increasingly becoming an important cause of morbidity and mortality in HIV positive individuals.⁷⁻¹² Individuals with HIV who become co-infected with HCV or HBV are less likely to clear the virus spontaneously, tend to have

Correspondence and reprint requests: Zobair M. Younossi, M.D., M.P.H.
Betty and Guy Beatty Center for Integrated Research
Claude Moore Health Education and Research Building
3300 Gallows Road, Falls Church, VA 22042, USA.
Phone: (703) 776-2540. Fax: (703) 776-4386
E-mail: zobair.younossi@inova.org

Manuscript received: May 15, 2013.

Manuscript accepted: July 17, 2013.

higher viral loads and are more likely to have progressive liver disease.^{9-10,12} HIV infected patients may also have a decreased response to viral hepatitis vaccines.^{7,8}

In addition to chronic viral hepatitis, NAFLD is becoming an important liver disease related to metabolic syndrome.¹³⁻¹⁵ In the era of cART, HIV-infected patients are susceptible to metabolic disorders such as abdominal obesity and lipodystrophy.¹³ However, in addition to metabolic syndrome, in HIV infected individuals, NAFLD and hepatic fibrosis may be caused by anti-HIV treatment regimens, specifically, non-nucleoside reverse transcriptase inhibitors such as stavudine and didanosine.^{16,17} Additionally, some protease inhibitors can contribute to abdominal lipodystrophy and interrupt glucose and lipid homeostasis leading to the clinical manifestation of NAFLD.¹⁸

Finally, excessive alcohol use can lead to progressive liver disease, especially in HIV-HCV co-infected individuals.^{19,20} Additionally, excessive alcohol consumption may lead to HIV progression and poor viral suppression.

In the context of this growing appreciation of the importance of chronic liver disease in HIV+ patients, our aim was to assess the prevalence and associations of chronic liver diseases in patients infected with HIV using a population-based data.

MATERIAL AND METHODS

Study population

For this study, we used five consecutive two-year cycles of the National Health and Nutrition Examination Survey (NHANES) collected by the National Center for Health Statistics between 1999 and 2008. NHANES is a nationwide survey conducted in the United States to collect information representing the health and nutritional status of the non-institutionalized civilian U.S. population. The survey includes an interview as well as standardized physical examination and data from blood samples collected at the exam centers. The description of these surveys has been reported in detail elsewhere.²¹ Participants were included in this study if they met the following criteria: at least 18 years of age, available demographic data together with the laboratory and clinical data necessary to rule in or rule out chronic liver disease (CLD). Furthermore, HIV data was available for participants aged 18-49 years who did not refuse HIV antibody test.

Study definitions

Eligible participants were considered HIV+ if their serum tested positive for HIV antibody by a triple test that included two enzyme immunoassays followed by a Western blot. Furthermore, eligible individuals who refused phlebotomy or who did not have a sufficient blood sample for the serum HIV assay, but who did not refuse HIV testing had their urine tested for HIV type 1 antibody using the Calypte HIV-1 Urine EIA (except for the cycle of 2007-2008 when the urine test was not conducted).²² As a result, individuals tested positive were also considered HIV+. And, for the purpose of the study, all antibody-negative individuals of 18-49 years of age were considered HIV-controls.

In this study, we included 3 major categories of chronic liver disease: alcoholic liver disease, chronic hepatitis C, and non-alcoholic fatty liver disease. Alcohol related liver disease (ALD) was defined as excessive alcohol use (20+ g/day for men, 10+ g/day for women) in the year before enrollment for NHANES in the presence of elevated serum aminotransferases (ALT > 40 U/L or AST > 37 U/L in men, ALT or AST > 31 U/L in women). Serologic tests for hepatitis C antibody were available in eligible participants and, if positive, HCV RNA was tested. Participants with positive HCV RNA were considered to have chronic hepatitis C (CH-C). Finally, subjects were presumed to have non-alcoholic fatty liver disease (NAFLD) if they had elevated serum aminotransferases (defined above) in the absence of any other evidence of chronic liver disease such as excessive alcohol use or positive viral hepatitis serology. We excluded patients with diagnosis of other causes chronic liver diseases. All together, individuals with ALD, CH-C and NAFLD were considered to have chronic liver disease (CLD) while those with normal aminotransferases, negative viral hepatitis serology and no history of excessive alcohol use were presumed to have no chronic liver disease.

Statistical analysis

The demographic and clinical parameters were compared between HIV+ individuals and HIV-controls using stratum-specific chi-square and t-test for a contrasted mean. To study independent predictors of CLD, we used multiple logistic regression analysis where demographic and clinical parameters were tested for independent association with CLD in HIV+ and HIV-individuals separately. P-values of 0.05 or less were considered potentially significant

unless stated otherwise. Statistical analyses were conducted using SUDAAN 10.1 (Research Triangle Institute, Research Triangle Park, NC). Sampling weights and stratum/sampling units that accounted for the complex survey design were used as recommended, and adjustment coefficients were applied when merging the five analytic cycles into one dataset according to the NHANES Analytic and Reporting Guidelines.²¹

RESULTS

The initial NHANES cohort (1999-2008) included 51,623 participants. Of these, 14,685 were considered eligible for the study and were considered the study cohort (Figure 1). After weighing on the basis of race/ethnicity, gender, and age, the cohort included $66.77 \pm 1.84\%$ non-Hispanic Whites, $12.22 \pm 1.06\%$ non-Hispanic Blacks and $10.22 \pm 1.05\%$ Hispanic Americans. Of the study cohort, 79 individuals ($0.43 \pm 0.08\%$) were HIV+.




Figure 1. Flowchart of sample selection.

Pairwise comparison of HIV+ individuals to HIV- controls is summarized in table 1. Specifically, HIV+ individuals were predominantly male ($76.34 \pm 5.07\%$ in HIV+ *vs.* $49.27 \pm 0.44\%$ in HIV-, $p = 0.0002$) and African American/Black ($51.73 \pm 7.78\%$ *vs.* $12.04 \pm 1.05\%$, respectively, $p < 0.0001$). HIV+ individuals were less likely to be obese ($\text{BMI} > 30$: $17.82 \pm 4.93\%$ in HIV+ *vs.* $29.83 \pm 0.74\%$ in HIV-, $p = 0.034$) and older (age: 38.31 ± 1.06 years in HIV+ *vs.* 34.50 ± 0.15 years in HIV-, $p = 0.0004$).

Chronic liver disease of any etiology was detected for $26.26 \pm 5.79\%$ of HIV+ individuals, which was significantly higher than in HIV- controls ($13.73 \pm 0.44\%$, $p = 0.03$). Considering different etiologies of CLD separately, a close to significant difference was noted only for CH-C: $7.25 \pm 2.81\%$ *vs.* $1.94 \pm 0.18\%$, $p = 0.06$. However, other liver diseases including NAFLD and ALD were not significantly different between HIV+ and HIV- individuals (Table 1). Although HBsAntigen+ was not significantly different between the two groups, other markers of HBV infection (presence of HBsAntibody and HBcAntibody) were highly more prevalent in HIV+ individuals.

Using multivariate analysis, after controlling for major confounders, HIV infection was independently associated with having chronic liver disease (OR (95% CI) = 1.96 (1.02-3.77), $p = 0.04$) (Table 2).

We also assessed the prevalence of HIV in patients with CLD. In fact, $0.83 \pm 0.21\%$ of individuals with CLD were HIV+. This included $0.69 \pm 0.40\%$ of those with ALD, $1.58 \pm 0.65\%$ of those with CH-C and $0.76 \pm 0.25\%$ of those with NAFLD. In controls without liver disease, the prevalence of HIV infection was $0.37 \pm 0.07\%$ which is significantly lower

Table 1. Clinical and demographic characteristics of the HIV+ individuals.

Parameter	HIV AB+ Cohort	HIV AB- Cohort	p
N	79	14,606	
Prevalence, %	0.43 ± 0.08		
Age, years	38.31 ± 1.06	34.50 ± 0.15	0.0004
Caucasian, %	30.92 ± 8.22	66.93 ± 1.83	< 0.0001
African-American, %	51.73 ± 7.78	12.04 ± 1.05	< 0.0001
Male, %	76.34 ± 5.07	49.27 ± 0.44	0.0002
Obesity ($\text{BMI} \geq 30$), %	17.82 ± 4.93	29.83 ± 0.74	0.0339
CLD, %	26.26 ± 5.79	13.73 ± 0.44	0.0341
ALD, %	3.89 ± 2.36	2.44 ± 0.20	0.5262
NAFLD, %	19.30 ± 5.76	10.90 ± 0.39	0.1522
CH-C (HCV RNA+), %	7.25 ± 2.81	1.94 ± 0.18	0.0665
Any HBV Markers	62.40 ± 5.65	24.00 ± 0.68	< 0.0001
HBcAb(+), %	50.95 ± 6.12	3.67 ± 0.25	< 0.0001
HBsAb(+), %	52.19 ± 5.90	23.30 ± 0.68	0.0003
HBsAg(+), %	0.00	0.03 ± 0.01	0.0629

Table 2. Independent predictors of CLD in the U.S. population of 18-49 years of age.

Parameter	OR (95% CI)	p
Age	1.03 (1.02-1.03)	< 0.0001
Male gender	2.15 (1.89-2.44)	< 0.0001
African-American race	0.68 (0.58-0.80)	< 0.0001
Obesity (BMI \geq 30)	2.10 (1.82-2.43)	< 0.0001
HIV infection	1.96 (1.02-3.77)	0.0424

as compared to those with CLD ($p = 0.03$) and those with CH-C ($p = 0.05$), and not significantly different from that in ALD and NAFLD (both $p > 0.1$).

DISCUSSION

Chronic liver diseases have become major causes of morbidity and mortality in HIV patients. In this population-based study, HIV infected individuals were more likely to have chronic liver disease as compared to non-infected controls. These findings are important since HIV infected individuals with CLD, especially those co-infected with HCV, are at significant risk for progressive liver disease and liver-related mortality. In fact, liver disease has become the most common non-AIDS related cause of death in the HIV population. Our data provides evidence of independent association between CLD and HIV at the population level. Additionally, both HCV and markers of HBV were both more common in HIV+ individuals, providing additional validity of our data.

Given these associations, it is imperative to screen individuals with HIV for CLD and reduce the risk of liver disease by vaccinating against HAV and HBV as well as by counseling against excessive alcohol use and modifying risk factors for NAFLD.

Once liver disease is identified in HIV-infected patients, steps can be taken not only to treat the underlying liver disease but also to closely monitor for its progression to cirrhosis or end-stage liver disease. Although anti-viral treatment for HCV in the HCV-HIV co-infected individuals may have lower response rates, the newer regimens are expected to provide better efficacy and improved treatment strategies.^{23,24} It is also important to note that access to treatment is also a major issue for HCV infected patients. This issue may be even more important for HCV-HIV co-infected patients and appropriate strategies are needed to help remove this barrier.

Our study does have some limitations. First, NHANES is a study looking at only civilian, non-institutionalized population in the United States

which may have underestimated the prevalence of HIV and other forms of liver disease by not accounting for incarcerated individuals, homeless persons, nursing home residents, and active military duty. In addition, NHANES screens for HIV in only for individuals between 18 to 49 years old. Also, some individuals with NAFLD may have been categorized as controls without liver disease if, at the time of examination, their liver enzymes were normal. Although other causes of chronic liver diseases were excluded by historical data, complete serologic/diagnostic laboratory tests were not available to fully exclude autoimmune hepatitis or hemochromatosis. However, the relatively low prevalence of these types of CLD in general population (as compared to HCV, NAFLD and ALD), their impact should be minimum. Also, limited sample size was also potentially responsible for some of the non-significant findings due to type II error. Nevertheless, the size of the initial study population and the in-depth nature of the available data make the study quite unique.

CONCLUSION

The HIV-infected individuals are at risk of morbidity and mortality due to chronic liver diseases. The increasing burden of CLD in HIV infected individuals has made liver-related mortality as the most common non-AIDS related cause of death in HIV positive individuals. It is important for health care providers involved in the care of HIV infected individuals to provide screening, early diagnosis and treatment of chronic liver diseases.

CONFLICT OF INTEREST

No conflict of interest for any authors.
Internal funding only.

REFERENCES

1. http://www.who.int/hiv/pub/progress_report2011/en/index.html Progress report 2011: Global HIV/AIDS response -

- Epidemic update and health sector progress towards universal access. Accessed May 1, 2012.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. *N Engl J Med* 1997; 337: 725-33.
 3. <http://www.cdc.gov/media/pressrel/r981007.htm> Accessed May 2, 2012.
 4. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study. *Arch Intern Med* 2006; 166: 1632-41.
 5. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. *J Acquir Immune Defic Syndr* 2006; 43: 27-34.
 6. Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C Group TDCoAEoA-HIVdS: factors associated with specific causes of death amongst HIV-positive individuals in the D: A: D study. *AIDS* 2010; 24: 1537-48.
 7. Laurence JC, Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. *Am J Med* 2005; 118(Suppl. 10A):75S.
 8. Brooks G. Prevention of viral hepatitis in HIV co-infection. *J Hepatol* 2006; 44(1 Suppl.): S104-7.
 9. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfecting patients. The Multivirc Group. *Hepatology* 1999; 30: 1054-8.
 10. Bonnard P, Lescure FX, Amiel C, et al. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfecting by HIV and HCV despite high CD4 cell count. *J Viral Hepat* 2007; 14: 806-11.
 11. Thio CL, Seaberg E.C, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). *Lancet* 2002; 360: 1921-6.
 12. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. *JAMA* 2000; 284(4): 450-6.
 13. Crum-Cianflone N, Dilay A, Collins G, et al. Nonalcoholic fatty liver disease among HIV-infected persons. *J Acquir Immune Defic Syndr* 2009; 50: 464-73.
 14. Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. *Hepatol* 2002; 35: 497-9.
 15. Lemoine M, Serfaty L, Capeau J. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. *Curr Opin Infect Dis* 2012; 25(1): 10-16.
 16. Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. *Clin Infect Dis* 2008; 47: 250-7.
 17. Akhtar MA, Mathieson K, Arey B, et al. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis. *Eur J Gastroenterol Hepatol* 2008; 20: 1194-204.
 18. Caron-Debarle M, Lagathu C, Boccara F, et al. HIV-associated lipodystrophy: from fat injury to premature aging. *Trends Molec Med* 2010; 16: 218-29.
 19. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. *J Acquir Immune Defic Syndr* 2006; 43: 411-17.
 20. Bonacini M. Alcohol use among patients with HIV infection. *Ann Hepatol* 2011; 10: 502-7.
 21. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Analytic Guidelines. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2005.
 22. http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/HIV_E.htm. Accessed October 4, 2012.
 23. Jensen DM. A new era of hepatitis C therapy begins. *N Engl J Med* 2011; 364(13): 1272-4.
 24. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. *N Engl J Med* 2011; 364(25): 2417-28.